- Home
- TGB vs CLDX Comparison
TGB vs CLDX Comparison
Compare TGB & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGB | CLDX |
|---|---|---|
| Founded | 1966 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | TGB | CLDX |
|---|---|---|
| Price | $8.22 | $24.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $5.00 | ★ $44.10 |
| AVG Volume (30 Days) | ★ 8.4M | 710.1K |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $428,559,326.00 | $2,599,000.00 |
| Revenue This Year | $10.35 | N/A |
| Revenue Next Year | $61.39 | $23.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.50 | N/A |
| 52 Week Low | $1.67 | $14.40 |
| 52 Week High | $8.37 | $30.50 |
Technical Indicators
Market Signals| Indicator | TGB | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 82.17 | 41.95 |
| Support Level | $7.70 | $25.40 |
| Resistance Level | $8.37 | $26.86 |
| Average True Range (ATR) | 0.42 | 1.13 |
| MACD | 0.13 | -0.08 |
| Stochastic Oscillator | 93.93 | 1.83 |
Price Performance
Historical ComparisonAbout TGB Taseko Mines Ltd.
Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.